<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Retin Cases Brief Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Retin Cases Brief Rep</journal-id>
      <journal-id journal-id-type="publisher-id">cabr</journal-id>
      <journal-title-group>
        <journal-title>Retinal Cases &amp; Brief Reports</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1935-1089</issn>
      <issn pub-type="epub">1937-1578</issn>
      <publisher>
        <publisher-name>Retinal Cases &amp; Brief Reports</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26444523</article-id>
      <article-id pub-id-type="pmc">4890820</article-id>
      <article-id pub-id-type="publisher-id">CABR-215-1408</article-id>
      <article-id pub-id-type="doi">10.1097/ICB.0000000000000228</article-id>
      <article-id pub-id-type="art-access-id">00021</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>PIMASERTIB AND SEROUS RETINAL DETACHMENTS</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>AlAli</surname>
            <given-names>Alaa</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bushehri</surname>
            <given-names>Ahmad</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff2">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Park</surname>
            <given-names>Jonathan C.</given-names>
          </name>
          <degrees>BSc, FRCOphth</degrees>
          <xref ref-type="aff" rid="aff1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Krema</surname>
            <given-names>Hatem</given-names>
          </name>
          <degrees>MD, MSc, FRCSEd</degrees>
          <xref ref-type="aff" rid="aff1">*</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Lam</surname>
            <given-names>Wai-Ching</given-names>
          </name>
          <degrees>MD, FRCSC</degrees>
          <xref ref-type="aff" rid="aff1">*</xref>
        </contrib>
        <aff id="aff1">Departments of <label>*</label>Ophthalmology and Vision Sciences, and</aff>
        <aff id="aff2"><label>&#x2020;</label>Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.</aff>
      </contrib-group>
      <author-notes>
        <corresp>Reprint requests: Wai-Ching Lam, MD, FRCSC, Department of Ophthalmology and Vision Sciences, Toronto Western Hospital, University of Toronto, 399 Bathurst Street, Room 6E-432, Toronto, Ontario M5T 2S8, Canada; e-mail: <email>waiching.lam@utoronto.ca</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Spring</season>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>04</day>
        <month>4</month>
        <year>2016</year>
      </pub-date>
      <volume>10</volume>
      <issue>2</issue>
      <fpage>191</fpage>
      <lpage>196</lpage>
      <permissions>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access">
          <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.</license-p>
        </license>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="cabr-10-191.pdf"/>
      <abstract abstract-type="toc">
        <p>This is the first case that describes bilateral, multifocal central serous retinopathy appearing 2 days after starting pimasertib for ovarian cancer and rapidly resolving 3 days after stopping pimasertib. Pimasertib is an orally bioavailable MEK 1 and 2 inhibitor with potential antineoplastic activity, that is, currently used in clinical trials for ovarian cancer. Multifocal serous retinal detachments have been reported with the use of MEK 1 and 2 inhibitors. The authors report the development of multifocal serous retinal detachments with the use of pimasertib in a 26-year-old woman with metastatic low-grade serous ovarian cancer that was initially treated in 2010, with laparoscopic right oophorectomy. The tumor showed evidence of progression in 2011 for which a hysterectomy, left salpingo-oophorectomy, omentectomy, and removal of the metastatic disease from the diaphragm was performed. This was followed by six cycles of carboplatin and taxol, along with one cycle of maintenance bevacizumab. There was no other medical history. The pathophysiology of this complication is still poorly understood.</p>
      </abstract>
      <abstract>
        <sec>
          <title>Purpose:</title>
          <p>To report a case of multifocal serous retinal detachments associated with pimasertib.</p>
        </sec>
        <sec>
          <title>Methods:</title>
          <p>The authors report a 26-year-old patient who developed bilateral multifocal serous retinal detachments appearing 2 days after starting pimasertib (as part of a clinical trial investigating its use in low-grade metastatic ovarian cancer) and rapidly resolving 3 days after stopping it.</p>
        </sec>
        <sec>
          <title>Conclusion:</title>
          <p>The mechanism of MEK inhibitor induced visual toxicity remains unclear. The pathophysiology of multifocal serous retinal detachments as a complication of pimasertib is still poorly understood.</p>
        </sec>
      </abstract>
      <kwd-group>
        <title>Key words:</title>
        <kwd>pimasertib</kwd>
        <kwd>MEK 1 and 2</kwd>
        <kwd>serous retinal detachments</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Case Report</title>
      <p>This unique case demonstrates bilateral serous retinal detachments as a side effect of pimasertib. Pimasertib is an orally bioavailable MEK 1 and 2 inhibitor with potential antineoplastic activity, that is, currently used in clinical trials for ovarian cancer.</p>
      <p>A 26-year-old woman, known to have metastatic low-grade serous ovarian cancer, started complaining of blurred vision 2 days after starting pimasertib. This was prescribed as part of a clinical trial, investigating the use of pimasertib versus placebo in the treatment of low-grade metastatic ovarian cancer. Pimasertib is given as a 60-mg tablet daily for 21 days followed by 7 days break and then the cycle is restarted. Snellen visual acuity at presentation was 20/25<sup>+2</sup> in each eye, intraocular pressure was 14 mmHg, and the anterior segment was unremarkable. Fundoscopy showed multifocal serous retinal detachment in both eyes (Figure <xref ref-type="fig" rid="F1">1</xref>). Optical coherence tomography demonstrated striking bilateral, multifocal serous retinal detachments (Figure <xref ref-type="fig" rid="F2">2</xref>, A and B). There was no history of steroid use.</p>
      <fig id="F1" position="float">
        <label>Fig. 1</label>
        <caption>
          <p>Fundoscopic exam showing multi-foci serous retinal detachments.</p>
        </caption>
        <graphic xlink:href="cabr-10-191-g001"/>
      </fig>
      <fig id="F2" position="float">
        <label>Fig. 2</label>
        <caption>
          <p><bold>A.</bold> Optical coherence tomography of the right eye showing multifocal serous retinal detachments. <bold>B.</bold> Optical coherence tomography of the left eye showing multifocal serous retinal detachments.</p>
        </caption>
        <graphic xlink:href="cabr-10-191-g002"/>
      </fig>
      <p>Three days after emergently stopping the pimasertib due to her ocular complaint, her vision rapidly returned to normal. Snellen visual acuity had improved to 20/20 in each eye and fundoscopy revealed resolution of the serous retinal detachments (Figure <xref ref-type="fig" rid="F3">3</xref>). Optical coherence tomography showed near complete resolution of the serous retinal detachments (Figure <xref ref-type="fig" rid="F4">4</xref>, A and B). Intravenous fluorescein fundus angiography was normal after stopping the medication (Figure <xref ref-type="fig" rid="F5">5</xref>).</p>
      <fig id="F3" position="float">
        <label>Fig. 3</label>
        <caption>
          <p>Fundoscopic examination showing resolution of serous retinal detachments.</p>
        </caption>
        <graphic xlink:href="cabr-10-191-g003"/>
      </fig>
      <fig id="F4" position="float">
        <label>Fig. 4</label>
        <caption>
          <p><bold>A.</bold> Optical coherence tomography of the right eye showing complete resolution of serous retinal detachments after completing pimasertib course. <bold>B.</bold> Optical coherence tomography of the left eye showing almost complete resolution of serous retinal detachments after completing pimasertib course.</p>
        </caption>
        <graphic xlink:href="cabr-10-191-g004"/>
      </fig>
      <fig id="F5" position="float">
        <label>Fig. 5</label>
        <caption>
          <p>Intravenous fundus fluorescein angiogram of both eyes was normal 3 days after stopping pimasertib.</p>
        </caption>
        <graphic xlink:href="cabr-10-191-g005"/>
      </fig>
      <p>Pimasertib is a MEK 1 and 2 inhibitor that modulates mitogen-activated protein kinases, which are a family of ubiquitous eukaryotic signal transduction enzymes that link extracellular stimuli to intracellular gene expression pathways allowing for various cellular responses, including adaptation and survival.<xref rid="R1" ref-type="bibr">1</xref> The classic mitogen-activated protein kinase cascade, the Ras/Raf/MEK/ERK cascade, is initiated by the binding of a ligand such as a growth factor, mitogen, or cytokine to its receptor at the cell surface. This cascade is now identified as a target opportunity for the treatment of low-grade ovarian carcinoma.</p>
      <p>Pimasertib has been used in clinical trials for the treatment of various types of cancer. Most common adverse events observed include diarrhea, rash, asthenia, anorexia, nausea, vomiting, peripheral edema, anemia, and visual disturbances including retinal vein occlusion, serous retinal detachment, and macular edema (Table <xref ref-type="table" rid="T1">1</xref>). The underlying pathology for central serous retinopathy is reversible after drug interruption followed by dose reduction.<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Current MEK Inhibitors Clinical Trials and Associated Percentages of Ocular Toxicity as Well as the Most Common Side Effects</p>
        </caption>
        <graphic xlink:href="cabr-10-191-g006"/>
      </table-wrap>
      <p>The mechanism of MEK inhibitor induced ocular toxicity remains unclear. Many of the molecules targeted by anticancer agents are also expressed in ocular tissues, which can explain the ocular toxicity causes by such medications. There is evidence that the mitogen-activated protein kinase pathway regulates tight junctions between retinal pigment epithelial cells so that MEK inhibitors may interfere with fluid transport, resulting in the accumulation of fluid beneath the retina.<xref rid="R4" ref-type="bibr">4</xref></p>
      <p>To our knowledge, this is the first case that describes bilateral, multifocal central serous retinopathy appearing 2 days after starting pimasertib for ovarian cancer and rapidly resolving 3 days after stopping pimasertib. Multifocal serous retinal detachments have been reported with the use of other MEK 1 and 2 inhibitors.<xref rid="R4" ref-type="bibr">4</xref> The pathophysiology of this complication is still poorly understood.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>None of the authors have any financial/conflicting interests to disclose.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>CR</given-names></name><name><surname>Oliver</surname><given-names>KE</given-names></name><name><surname>Farley</surname><given-names>JH</given-names></name></person-group>
<article-title>MEK1/2 inhibitors in the treatment of gynecologic malignancies</article-title>. <source>Gynecol Oncol</source>
<year>2014</year>;<volume>133</volume>:<fpage>128</fpage>&#x2013;<lpage>137</lpage>.<pub-id pub-id-type="pmid">24434059</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delord</surname><given-names>J</given-names></name><name><surname>Houede</surname><given-names>N</given-names></name><name><surname>Awada</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors</article-title>. <source>J Clin Oncol</source>
<year>2010</year>;<volume>28</volume>:<fpage>15</fpage>.<pub-id pub-id-type="pmid">19933920</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houede</surname><given-names>N</given-names></name><name><surname>Faivre</surname><given-names>SJ</given-names></name><name><surname>Awada</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies</article-title>. <source>J Clin Oncol</source>
<year>2011</year>;<volume>29</volume>:<fpage>15</fpage>.</mixed-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCannel</surname><given-names>T</given-names></name><name><surname>Chmlelowski</surname><given-names>B</given-names></name><name><surname>Finn</surname><given-names>RS</given-names></name><etal/></person-group>
<article-title>Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metatatic cancer</article-title>. <source>JAMA</source>
<year>2014</year>;<volume>132</volume>:<fpage>1005</fpage>&#x2013;<lpage>1009</lpage>.</mixed-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinehart</surname><given-names>J</given-names></name><name><surname>Adjei</surname><given-names>A</given-names></name><name><surname>LoRusso</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small cell lung, breast, colon, and pan- creatic cancer</article-title>. <source>J Clin Oncol</source>
<year>2004</year>;<volume>22</volume>:<fpage>4456</fpage>&#x2013;<lpage>4462</lpage>.<pub-id pub-id-type="pmid">15483017</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerji</surname><given-names>U</given-names></name><name><surname>Camidge</surname><given-names>DR</given-names></name><name><surname>Verheul</surname><given-names>HMW</given-names></name><etal/></person-group>
<article-title>The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer</article-title>. <source>Clin Cancer Res</source>
<year>2010</year>;<volume>16</volume>:<fpage>1613</fpage>&#x2013;<lpage>1623</lpage>.<pub-id pub-id-type="pmid">20179232</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilmartin</surname><given-names>AG</given-names></name><name><surname>Bleam</surname><given-names>MR</given-names></name><name><surname>Groy</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition</article-title>. <source>Clin Cancer Res</source>
<year>2011</year>;<volume>17</volume>:<fpage>989</fpage>&#x2013;<lpage>1000</lpage>.<pub-id pub-id-type="pmid">21245089</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Garcia</surname><given-names>M</given-names></name><name><surname>Banerji</surname><given-names>U</given-names></name><name><surname>Albanell</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>First-in-human, phase I dose- escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors</article-title>. <source>Clin Cancer Res</source>
<year>2012</year>;<volume>18</volume>:<fpage>4806</fpage>&#x2013;<lpage>4819</lpage>.<pub-id pub-id-type="pmid">22761467</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LoRusso</surname><given-names>PM</given-names></name><name><surname>Krishnamurthi</surname><given-names>SS</given-names></name><name><surname>Rinehart</surname><given-names>JJ</given-names></name><etal/></person-group>
<article-title>Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers</article-title>. <source>Clin Cancer Res</source>
<year>2010</year>;<volume>16</volume>:<fpage>1924</fpage>&#x2013;<lpage>1937</lpage>.<pub-id pub-id-type="pmid">20215549</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
